Page last updated: 2024-11-03

risperidone and Anorexia Nervosa

risperidone has been researched along with Anorexia Nervosa in 9 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Anorexia Nervosa: An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)

Research Excerpts

ExcerptRelevanceReference
"The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa."9.15A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. ( Dodge, M; Ellert, S; Frank, G; Gardner, R; Gralla, J; Hagman, J; O'Lonergan, T; Sigel, E; Wamboldt, MZ, 2011)
"Current Diagnostic and Statistical Manual of Mental Disorders (DSM)-5-based research provides limited data on the use of risperidone on children and adolescents with anorexia nervosa (AN) mainly in small-sample/case report studies."8.31The role of risperidone in the treatment of children and adolescents with anorexia nervosa. ( Bergonzini, L; Parmeggiani, A; Pettenuzzo, I; Pruccoli, J, 2023)
"The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa."5.15A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. ( Dodge, M; Ellert, S; Frank, G; Gardner, R; Gralla, J; Hagman, J; O'Lonergan, T; Sigel, E; Wamboldt, MZ, 2011)
"Current Diagnostic and Statistical Manual of Mental Disorders (DSM)-5-based research provides limited data on the use of risperidone on children and adolescents with anorexia nervosa (AN) mainly in small-sample/case report studies."4.31The role of risperidone in the treatment of children and adolescents with anorexia nervosa. ( Bergonzini, L; Parmeggiani, A; Pettenuzzo, I; Pruccoli, J, 2023)
"Olanzapine is the treatment most frequently prescribed and studied with 7 randomized double-blind controlled trials."3.01Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review. ( Blanchet, C; Carretier, E; Guessoum, SB; Ludot, M; Moro, MR; Thorey, S, 2023)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's3 (33.33)24.3611
2020's2 (22.22)2.80

Authors

AuthorsStudies
Thorey, S1
Blanchet, C1
Guessoum, SB1
Moro, MR1
Ludot, M1
Carretier, E1
Pruccoli, J1
Bergonzini, L1
Pettenuzzo, I1
Parmeggiani, A1
Couturier, J1
Isserlin, L1
Spettigue, W1
Norris, M1
Moga, DE1
Cabaniss, DL1
Marcus, ER1
Walsh, BT1
Kahn, DA1
Hebebrand, J1
Hagman, J1
Gralla, J1
Sigel, E1
Ellert, S1
Dodge, M1
Gardner, R1
O'Lonergan, T1
Frank, G1
Wamboldt, MZ1
Mehler-Wex, C1
Romanos, M1
Kirchheiner, J1
Schulze, UM1
Fisman, S1
Steele, M1
Short, J1
Byrne, T1
Lavallee, C1
Newman-Toker, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa[NCT00140426]Phase 441 participants (Actual)Interventional2004-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Body Image Software (BIS) - Difference Limen (DL)

"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image, and also completes a task that determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS-DL was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. There are no subscales. Interpreting the DL occurs by referencing it to DL= 0, which would reflect a total inability to detect size differences, which has never occurred in studies using the BIS program." (NCT00140426)
Timeframe: monthly

Interventionunits on a scale (Mean)
Risperidone or Placebo-0.19
Risperidone-1.16

Body Image Software (BIS) - Point of Subjective Equality (PSE)

"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image, and also completes a task that determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS -PSE was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. Interpreting the PSE is how it compares to a PSE = 0, which is no distortion in body size." (NCT00140426)
Timeframe: monthly

Interventionunits on a scale (Mean)
Risperidone or Placebo-0.32
Risperidone-2.18

Body Image Software (BIS): Average Desired Thinness

"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image. The BIS program calculates the difference between their actual image, and how much they have adjusted the image to represent their desired image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS - Average Desired Thinness score was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. . There are no subscales." (NCT00140426)
Timeframe: monthly

Interventionunits on a scale (Mean)
Risperidone or Placebo1.88
Risperidone-1.42

Body Image Software (BIS): Average Distortion

"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer using the direction to adjust their image to how they see themselves right now, this determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in the BIS Average Distortion score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. There are no subscales. The BIS program calculates the difference between their actual image and the size of the image they have adjusted the digital image to based on their perception of how they see themselves right now" (NCT00140426)
Timeframe: monthly

Interventionunits on a scale (Mean)
Risperidone or Placebo-0.22
Risperidone1.40

Change in Eating Disorder Inventory (EDI)-2 Score for Body Dissatisfaction (BD)

"change in Eating Disorder Inventory (EDI) 2-score for Body Dissatisfaction (BD).~Lower scores are better on this scale. Higher scores indicate the subject has greater body dissatisfaction. BD is one of the 8 subscales of the EDI-2. 9 of the 91 questions in the EDI-2 scale constitute this subscale. The score range is 0-27. Subjects completed the EDI-2 at baseline and monthly during study participation (range 0 to 18 weeks). Change in the BD subscale score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly

Interventionunits on a scale (Mean)
Placebo0.82
Risperidone2.67

Change in Eating Disorder Inventory-2 Drive for Thinness Subscale (DT)

"Eating Disorder Inventory -2 - Subscale : Drive for Thinness Subscale (DT). Lower scores are better on this scale and indicate less cognitive focus on drive for thinness.~The EDI 2 is a 91 item scale with 8 subscales - (Drive for thinness, Bulimia, body dissatisfaction, ineffectiveness, perfection, interpersonal distrust, interoceptive awareness and maturity fears.). The DT subscale was used for this outcome. Respondents rate each item as usually , often, sometimes, rarely or never. Subscale scores are computed by summing all item scores for each subscale. There are 7 items in the DT subscale (questions 1,7,11,16,25,32 and 49). the subscale score range is 0-21. The EDI-2 was completed by subjects at baseline and then monthly during study participation (range 0 -18 weeks). Change in the DT subscale score was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: month

Interventionunits on a scale (Mean)
Placebo1.36
Risperidone3.93

Change in Leptin Levels

Leptin levels were measured by serum blood draws, results reports in nanograms / ml (ng/ml). (NCT00140426)
Timeframe: Week 0 and week 7

Interventionng/ml (Mean)
Placebo0.88
Risperidone3.27

Change in Prolactin Levels

Prolactin serum blood levels, measured in nanograms / ml (NCT00140426)
Timeframe: week 0 and week 7

Interventionng/ml (Mean)
Placebo-5.18
Risperidone38.27

Change in Ratings of Anxiety Symptoms on the Multidimensional Anxiety Scale for Children (MASC)

"The Multidimensional Anxiety Scale for Children (MASC) is a self report measure completed by the subject that measures anxiety symptoms.~Higher scores indicate greater anxiety. A score of over 50 is significant for anxiety~Change in MASC scores was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly to study end point

Interventionunits on a scale (Mean)
Placebo7.41
Risperidone7.87

Color A Person Test (CAPT)

"Color A Person Test (CAPT) - Subjects color an outlined image of a body to indicate body dissatisfaction (red (5)= very dissatisfied, Yellow, dissatisfied, black, neutral, green satisfied, blue very satisfied (1). The outline is divided into16 sections for scoring. The CAPT was completed at baseline and monthly during study participation.~Total CAPT scores were calculated by adding the total score and dividing by 16. Score range is 1-5. Lower scores indicate less body dissatisfaction.~Change in the CAPT score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly

Interventionunits on a scale (Mean)
Risperidone or Placebo0.03
Risperidone0.22

Hazard Ratio for Time to Reaching Ease Of Eating Level 3 From Start of Study (Normal Eating Behavior)

"The Ease of Eating Scale (EOES) is a 14 item scale which measures Food avoidance behaviors (FABs). The scale is rated by staff observing a subject eating a meal or snack. 0 = normal eating behavior, maximum score 28.~Higher scores indicate more food avoidance behaviors, such as taking small bites, taking > 30 seconds between bites (slow eating), etc.~EOE was completed for each meal a subject ate in the program and scores were averaged for each week in the study and entered in the data base.~Change in EOES score was calculated by evaluating change over time. This measure was only used in Phase 1 of the study, for days the subjects were in the treatment program." (NCT00140426)
Timeframe: weekly up to study endpoint: reaching target weight and maintaining for 1 month

Interventionhazard ratio (Number)
Placebo0.85
Risperidone1

Time to Reach 90% IBW and Maintain for 1 Month, Stratified by IBW <80% at Start of Study

The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. These estimates were produced using Kaplan-Meier probabilities. (NCT00140426)
Timeframe: 0 - 18 weeks

Interventionweeks (Mean)
Placebo10.1
Risperidone12.9

Time to Reach 90% Ideal Body Weight (IBW) and Maintain for 1 Month, Stratified by >=80% at Start of Study

The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. These estimates were produced using Kaplan-Meier probabilities. This was measured weekly from 0-18 weeks. (NCT00140426)
Timeframe: weekly

Interventionweeks (Mean)
Placebo10.7
Risperidone8.1

Reviews

3 reviews available for risperidone and Anorexia Nervosa

ArticleYear
Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.
    PloS one, 2023, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Anorexia Nervosa; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Ol

2023
Psychotropic Medication for Children and Adolescents with Eating Disorders.
    Child and adolescent psychiatric clinics of North America, 2019, Volume: 28, Issue:4

    Topics: Adolescent; Anorexia Nervosa; Avoidant Restrictive Food Intake Disorder; Binge-Eating Disorder; Buli

2019
Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports.
    European eating disorders review : the journal of the Eating Disorders Association, 2008, Volume: 16, Issue:2

    Topics: Adolescent; Anorexia Nervosa; Antipsychotic Agents; Benzodiazepines; Child; Dibenzothiazepines; Fema

2008

Trials

1 trial available for risperidone and Anorexia Nervosa

ArticleYear
A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2011, Volume: 50, Issue:9

    Topics: Adolescent; Adult; Anorexia Nervosa; Antipsychotic Agents; Body Image; Body Weight; Child; Double-Bl

2011

Other Studies

5 other studies available for risperidone and Anorexia Nervosa

ArticleYear
The role of risperidone in the treatment of children and adolescents with anorexia nervosa.
    Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:6

    Topics: Adolescent; Anorexia Nervosa; Antipsychotic Agents; Body Mass Index; Child; Feeding and Eating Disor

2023
Religious delusions in an evangelical Christian woman with anorexia nervosa.
    Journal of psychiatric practice, 2009, Volume: 15, Issue:6

    Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Female; Hospitaliz

2009
Pharmacotherapy of anorexia nervosa: more questions than answers.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2011, Volume: 50, Issue:9

    Topics: Anorexia Nervosa; Antipsychotic Agents; Female; Humans; Risperidone

2011
Case study: anorexia nervosa and autistic disorder in an adolescent girl.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1996, Volume: 35, Issue:7

    Topics: Adolescent; Anorexia Nervosa; Antipsychotic Agents; Autistic Disorder; Behavior Therapy; Combined Mo

1996
Risperidone in anorexia nervosa.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2000, Volume: 39, Issue:8

    Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Child; Delusions; Dose-Response Relationship, Drug; F

2000